WO2001072831A3 - Immunoregulator - Google Patents

Immunoregulator Download PDF

Info

Publication number
WO2001072831A3
WO2001072831A3 PCT/NL2001/000259 NL0100259W WO0172831A3 WO 2001072831 A3 WO2001072831 A3 WO 2001072831A3 NL 0100259 W NL0100259 W NL 0100259W WO 0172831 A3 WO0172831 A3 WO 0172831A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune
immunoregulator
nmpf
disease
treating
Prior art date
Application number
PCT/NL2001/000259
Other languages
French (fr)
Other versions
WO2001072831A2 (en
Inventor
Nisar Ahmed Khan
Robbert Benner
Original Assignee
Univ Erasmus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020027012952A priority Critical patent/KR100800876B1/en
Priority to JP2001571762A priority patent/JP5172064B2/en
Priority to DK07108784T priority patent/DK1887016T3/en
Priority to AU48913/01A priority patent/AU781632B2/en
Application filed by Univ Erasmus filed Critical Univ Erasmus
Priority to DE60136169T priority patent/DE60136169D1/en
Priority to NZ521703A priority patent/NZ521703A/en
Priority to DK01922133T priority patent/DK1272515T3/en
Priority to EP07108784A priority patent/EP1887016B1/en
Priority to IL15194501A priority patent/IL151945A0/en
Priority to SI200130892T priority patent/SI1272515T1/en
Priority to CA2407046A priority patent/CA2407046C/en
Priority to EP01922133A priority patent/EP1272515B1/en
Publication of WO2001072831A2 publication Critical patent/WO2001072831A2/en
Publication of WO2001072831A3 publication Critical patent/WO2001072831A3/en
Priority to IL151945A priority patent/IL151945A/en
Priority to US10/262,522 priority patent/US7365155B2/en
Priority to HK03104599.4A priority patent/HK1052360B/en
Priority to US10/753,510 priority patent/US7358330B2/en
Priority to US10/821,240 priority patent/US20050037430A1/en
Priority to AU2005205734A priority patent/AU2005205734B2/en
Priority to AU2005205750A priority patent/AU2005205750B2/en
Priority to US11/346,450 priority patent/US7576174B2/en
Priority to US11/600,294 priority patent/US8680059B2/en
Priority to US11/859,265 priority patent/US20080076719A1/en
Priority to US12/069,401 priority patent/US20080306009A1/en
Priority to US13/065,317 priority patent/USRE43309E1/en
Priority to US13/065,316 priority patent/USRE43279E1/en
Priority to US13/065,318 priority patent/USRE43140E1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides among others an immunoregulator (NMPF), use of an NMPF in preparing a pharmaceutical composition for treating an immune-mediated disorder, a pharmaceutical composition and a method for treating an immune-mediated disorder.
PCT/NL2001/000259 1998-05-20 2001-03-29 Immunoregulator WO2001072831A2 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
NZ521703A NZ521703A (en) 2000-03-29 2001-03-29 Pharmaceutical composition comprising an immunoregulator peptide from the beta-loop 2 region of beta-HGC capable of regulating Th1 and/or Th2 cell activity
DK07108784T DK1887016T3 (en) 2000-03-29 2001-03-29 Human chorionic gonadotropin (HCG) fragments as immunoregulator
AU48913/01A AU781632B2 (en) 2000-03-29 2001-03-29 Immunoregulator
EP07108784A EP1887016B1 (en) 2000-03-29 2001-03-29 Fragments of human chorionic gonadotropin (hcg) as immunoregulator
DE60136169T DE60136169D1 (en) 2000-03-29 2001-03-29 IMMUNE ADJUSTER
DK01922133T DK1272515T3 (en) 2000-03-29 2001-03-29 Immune Regulator
SI200130892T SI1272515T1 (en) 2000-03-29 2001-03-29 Immunoregulator
KR1020027012952A KR100800876B1 (en) 2000-03-29 2001-03-29 Immunoregulator
IL15194501A IL151945A0 (en) 2000-03-29 2001-03-29 Immunoregulator
JP2001571762A JP5172064B2 (en) 2000-03-29 2001-03-29 Immunomodulator
CA2407046A CA2407046C (en) 2000-03-29 2001-03-29 Immunoregulator
EP01922133A EP1272515B1 (en) 2000-03-29 2001-03-29 Immunoregulator
IL151945A IL151945A (en) 2000-03-29 2002-09-26 Immunoregulatory peptides and use thereof
US10/262,522 US7365155B2 (en) 2000-03-29 2002-09-30 Immunoregulator
HK03104599.4A HK1052360B (en) 2000-03-29 2003-06-27 Immunoregulator
US10/753,510 US7358330B2 (en) 2001-03-29 2004-01-07 Immunoregulatory compositions
US10/821,240 US20050037430A1 (en) 2000-03-29 2004-04-08 Methods and uses for protein breakdown products
AU2005205734A AU2005205734B2 (en) 2000-03-29 2005-08-31 Immunoregulator
AU2005205750A AU2005205750B2 (en) 2000-03-29 2005-08-31 Immunoregulator
US11/346,450 US7576174B2 (en) 2000-03-29 2006-02-02 Compositions capable of reducing elevated blood urea concentration
US11/600,294 US8680059B2 (en) 1998-05-20 2006-11-15 Oligopeptide acetate and formulations thereof
US11/859,265 US20080076719A1 (en) 2001-03-29 2007-09-21 Immunoregulatory compositions
US12/069,401 US20080306009A1 (en) 2001-03-29 2008-02-08 Immunoregulatory compositions
US13/065,317 USRE43309E1 (en) 2000-03-29 2011-03-17 Immunoregulatory compositions
US13/065,316 USRE43279E1 (en) 2000-03-29 2011-03-17 Compositions capable of reducing elevated blood urea concentration
US13/065,318 USRE43140E1 (en) 2000-03-29 2011-03-17 Immunoregulator

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00201139.3 2000-03-29
EP00201139A EP1138692A1 (en) 2000-03-29 2000-03-29 Fragments of human chorionic gonadotropin (hcg) as immunoregulator

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2002/000639 Continuation-In-Part WO2003029292A2 (en) 2000-03-29 2002-10-04 Gene regulatory peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/262,522 Continuation US7365155B2 (en) 1998-05-20 2002-09-30 Immunoregulator

Publications (2)

Publication Number Publication Date
WO2001072831A2 WO2001072831A2 (en) 2001-10-04
WO2001072831A3 true WO2001072831A3 (en) 2002-04-25

Family

ID=8171269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2001/000259 WO2001072831A2 (en) 1998-05-20 2001-03-29 Immunoregulator

Country Status (18)

Country Link
US (2) US7365155B2 (en)
EP (3) EP1138692A1 (en)
JP (1) JP5172064B2 (en)
KR (1) KR100800876B1 (en)
AT (2) ATE411340T1 (en)
AU (1) AU781632B2 (en)
CA (1) CA2407046C (en)
CY (2) CY1108706T1 (en)
DE (2) DE60136577D1 (en)
DK (2) DK1887016T3 (en)
ES (2) ES2317620T3 (en)
HK (1) HK1052360B (en)
IL (2) IL151945A0 (en)
NZ (1) NZ521703A (en)
PT (2) PT1887016E (en)
SG (1) SG127739A1 (en)
SI (2) SI1887016T1 (en)
WO (1) WO2001072831A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43309E1 (en) 2000-03-29 2012-04-10 Biotempt B.V. Immunoregulatory compositions

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
EP1466611A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Use of HCG derived peptides in the treatment of iatrogenic diseases
KR101184833B1 (en) * 2003-04-08 2012-09-20 바이오템프트, 비.브이. Compositions for mucosal and oral administration comprising HCG fragments
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
EP1466613A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Compositions for mucosal and oral administration comprising hCG fragments
EP1466612A1 (en) * 2003-04-08 2004-10-13 Biotempt B.V. Treatment of inflammation and sepsis with hCG derived peptides
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
WO2006090874A1 (en) * 2005-02-25 2006-08-31 Nihon University Method of analyzing mammalian t cell cytokines, method of evaluating all of related diseases and analysis of prevention and therapy therefor
WO2007004869A2 (en) * 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
DE102005054454A1 (en) * 2005-11-09 2007-06-28 Universität Duisburg-Essen Use of chorionic gonadotropin as immunosuppressant
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
SG178780A1 (en) * 2007-02-12 2012-03-29 Biotempt Bv Treatment of trauma-hemorrhage with short oligopeptides
US20080217002A1 (en) * 2007-03-07 2008-09-11 Floyd Randolph Simonds Sand control screen having a micro-perforated filtration layer
WO2009085180A1 (en) * 2007-12-20 2009-07-09 The Feinstein Institute For Medical Research Treatment of sepsis and inhibition of mif by d-t4
EP2109054A1 (en) 2008-04-09 2009-10-14 Biotempt B.V. Methods for identifying biologically active peptides and predicting their function
EP2490021A1 (en) 2011-02-18 2012-08-22 Biotempt B.V. Modulators of PRR and GPCR signalling
CN104415162B (en) * 2013-08-21 2018-05-15 常州市肿瘤医院 Treat Chinese medicine composition of leukopenia after chemoradiotherapy and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049721A1 (en) * 1996-06-24 1997-12-31 University Of Maryland Biotechnology Institute Methods of treatment of wasting syndrome based on administration of derivatives of human chorionic gonadotropin
WO1999059617A2 (en) * 1998-05-20 1999-11-25 Erasmus Universiteit Rotterdam Immunoregulator

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571336A (en) 1983-08-25 1986-02-18 Endorphin, Inc. Immune stimulation
US4977244A (en) 1985-06-27 1990-12-11 The United States Of America As Represented By The Department Of Health And Human Services Uromodulin and a process of purifying it
US4855285A (en) * 1985-12-04 1989-08-08 The Ohio State University Research Foundation Antigenic modification of polypeptides
JPH0680015B2 (en) 1986-05-12 1994-10-12 ザ ウエルカム ファウンデーション リミテッド Pharmaceutical composition
US5055447A (en) 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5308834A (en) 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US6051596A (en) 1990-08-10 2000-04-18 Anormed, Inc. Immunosuppressive compositions
US5958413A (en) 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
JPH06508029A (en) 1991-05-17 1994-09-14 カイロン　コーポレイション Inhibitor of NF-↓kB transcriptional activator and its use
DE4138621A1 (en) 1991-11-25 1993-06-17 Boehringer Ingelheim Int METHOD FOR SCREENING SUBSTANCES WITH MODULATING EFFECT ON A RECEPTACLE-RELATED CELLULAR SIGNAL TRANSMISSION PATH
PT633929E (en) * 1992-04-01 2004-07-30 Merix Bioscience Inc METHOD FOR PROLIFERATION (IN VITRO) OF DENTIFICAL CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENES
ES2103854T3 (en) 1992-05-30 1997-10-01 Sikiric Predrag PEPTIDES WITH ORGAN PROTECTIVE ACTIVITY, PROCEDURE FOR THE PREPARATION OF THE SAME AND ITS USE IN THERAPY.
US5436270A (en) 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
US5380668A (en) 1993-07-06 1995-01-10 University Of Utah Research Foundation Compounds having the antigenicity of hCG
US5837478A (en) 1993-12-23 1998-11-17 Icos Corporation Method of identifying modulators of binding between and VCAM-1
US5677275A (en) 1994-08-05 1997-10-14 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
US5700781A (en) 1994-10-04 1997-12-23 Harris; Pamela Jo Method for treating Kaposi's sarcoma and HIV infections
US5851997A (en) 1994-10-04 1998-12-22 Harris; Pamela Jo Use of human chorionic gonadotropin as an immune-potentiating antiviral agent
SE520730C2 (en) 1995-01-20 2003-08-19 Eskil Elmer Treatment of brain ischemia and brain damage with a neuroprotective drug
WO1996032412A1 (en) 1995-04-13 1996-10-17 Chugai Seiyaku Kabushiki Kaisha PEPTIDE SUPPRESSING IxBα PHOSPHORYLATION
WO1996033218A1 (en) 1995-04-21 1996-10-24 Allelix Biopharmaceuticals Inc. Anti-haemorrhagic peptides
US6361992B1 (en) 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US5997871A (en) * 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
GB9617021D0 (en) 1996-08-13 1996-09-25 Salpep Biotechnology Inc Novel peptides for treatment of inflammation and shock
EP1005354A4 (en) 1997-02-07 2002-05-15 Univ Jefferson Peptide mimetics of the cytokine receptor gamma chain
EP0979096B1 (en) 1997-02-15 2003-05-14 Millennium Pharmaceuticals, Inc. Treatment of infarcts through inhibition of nf-kappab
US5801193A (en) 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
DE19735587B4 (en) 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum A peptide having a radioprotective effect, a cosmetic or pharmaceutical composition containing the same, a nucleic acid encoding the same, a preparation process for this peptide and the use as a radioprotective agent
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6652860B1 (en) 1997-12-12 2003-11-25 University Of Western Ontario Peptide, apoEp 1.B, compositions and uses thereof
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
RU2139085C1 (en) 1998-06-23 1999-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Agent stimulating reparative processes and method of its use
WO2000017348A1 (en) 1998-09-17 2000-03-30 Hopital Sainte-Justine G protein-coupled receptor agonists or antagonists
IL143219A0 (en) 1998-11-20 2002-04-21 Mount Sinai Hospital Corp Peptides that modulate the interaction of b class ephrins and pdz domains
US6507788B1 (en) 1999-02-25 2003-01-14 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
WO2000053621A2 (en) 1999-03-09 2000-09-14 Jeffrey Lynn Haddox Synthetic complementary peptides and ophthalmologic uses thereof
US20030148955A1 (en) 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
RU2157233C1 (en) 1999-05-11 2000-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Tetrapeptide showing geroprotective activity, pharmacological agent based on thereof and method of its use
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
CA2378480A1 (en) 1999-08-09 2001-02-15 Tripep Ab Pharmaceutical compositions containing tripeptides
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
BR0014742A (en) 1999-10-15 2002-08-27 Histatek Llc Method for inhibiting a pro-inflammatory response from a mononuclear cell and polymorphonuclear cell from human peripheral blood, or a fixed tissue cell, when contacted with a pro-inflammatory agent, receptor complex, and, method for the identification of a g kinase protein signal pathway modifying agent
RU2155063C1 (en) 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Tetrapeptide stimulating functional activity of neurons, pharmacological agent based on thereof and method of its use
WO2001036454A1 (en) 1999-11-18 2001-05-25 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
DE60110396T2 (en) 2000-01-14 2006-01-19 Larson, Richard S., Albuquerque PEPTIDIC INHIBITORS OF LFA-1 / ICAM-1 INTERACTION
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
AU2001245537A1 (en) 2000-03-10 2001-09-24 Monsanto Company Anti-hypertensive peptides
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US6783757B2 (en) 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US6586403B1 (en) 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US20020155106A1 (en) 2000-12-01 2002-10-24 Hammond David J. Method of identifying a ligand for a target molecule
WO2002085117A1 (en) 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
US20030220259A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20030224995A1 (en) 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220260A1 (en) 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20030220257A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20040013661A1 (en) 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US20030220261A1 (en) 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US7217507B2 (en) 2002-04-15 2007-05-15 The American National Red Cross Method for detecting ligands and targets in a mixture
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
WO2007004869A2 (en) 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049721A1 (en) * 1996-06-24 1997-12-31 University Of Maryland Biotechnology Institute Methods of treatment of wasting syndrome based on administration of derivatives of human chorionic gonadotropin
WO1999059617A2 (en) * 1998-05-20 1999-11-25 Erasmus Universiteit Rotterdam Immunoregulator

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43309E1 (en) 2000-03-29 2012-04-10 Biotempt B.V. Immunoregulatory compositions

Also Published As

Publication number Publication date
HK1052360B (en) 2009-05-08
WO2001072831A2 (en) 2001-10-04
EP1887016A1 (en) 2008-02-13
ATE414104T1 (en) 2008-11-15
EP1272515A2 (en) 2003-01-08
CY1110259T1 (en) 2015-01-14
EP1272515B1 (en) 2008-10-15
US20030166556A1 (en) 2003-09-04
KR20030060768A (en) 2003-07-16
DE60136169D1 (en) 2008-11-27
DE60136577D1 (en) 2008-12-24
ES2317620T3 (en) 2009-04-16
EP1138692A1 (en) 2001-10-04
US7365155B2 (en) 2008-04-29
USRE43140E1 (en) 2012-01-24
CA2407046C (en) 2011-02-15
JP2004503468A (en) 2004-02-05
CA2407046A1 (en) 2001-10-04
AU4891301A (en) 2001-10-08
PT1272515E (en) 2009-01-23
ATE411340T1 (en) 2008-10-15
EP1887016B1 (en) 2008-11-12
PT1887016E (en) 2009-02-20
CY1108706T1 (en) 2014-04-09
DK1272515T3 (en) 2009-02-09
JP5172064B2 (en) 2013-03-27
SI1272515T1 (en) 2009-04-30
AU781632B2 (en) 2005-06-02
IL151945A (en) 2010-04-29
SG127739A1 (en) 2006-12-29
SI1887016T1 (en) 2009-04-30
ES2315278T3 (en) 2009-04-01
DK1887016T3 (en) 2009-03-02
NZ521703A (en) 2005-06-24
IL151945A0 (en) 2003-04-10
KR100800876B1 (en) 2008-02-04
HK1052360A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
WO2001072831A3 (en) Immunoregulator
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
DE69911401D1 (en) Immunoregulator
WO2003030934A3 (en) Cpg formulations and related methods
UA85993C2 (en) Conjugate of a bacterial superantigen and antibody moiety, pharmaceutical composition containing thereof and method for treatment of cancer in mammals
AU2002303817A1 (en) Compositions and methods for treating or preventing convulsions or seizures
SE9603725D0 (en) New teatment
MX9802809A (en) Urease for the treatment of helicobacter pylori infections.
AU2003255429A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
UA35854A (en) Method for treating latent silicotuberculosis
UA29106A (en) The method for treatment of vibration disease
UA32288A (en) Method for treating degenerative and inflammatory processes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 151945

Country of ref document: IL

Ref document number: 2407046

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 571762

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027012952

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 48913/01

Country of ref document: AU

Ref document number: 10262522

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 521703

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/1756/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001922133

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001922133

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027012952

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 521703

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 48913/01

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 521703

Country of ref document: NZ